Wilmington, Delaware, Feb. 04, 2025 (GLOBE NEWSWIRE) — Allied Market Research published a report, titled, “Clot Management Devices Market by Product (Neurovascular Embolectomy Devices, Embolectomy Balloon Catheters, Percutaneous Thrombectomy Devices, Catheter-Directed Thrombolysis Devices, and Inferior Vena Cava Filters) and End User (Hospitals and Other End Users): Global Opportunity Analysis and Industry Forecast, 2024-2035″. According to the report, the “clot management devices market” was valued at $2.1 billion in 2023, and is estimated to reach $4.3 billion by 2035, growing at a CAGR of 6.2% from 2024 to 2035.
Request Sample of the Report on Global Clot Management Devices Market 2035 – https://www.alliedmarketresearch.com/request-sample/5477
Prime determinants of growth
Rise in prevalence of thromboembolic disorders and surge in trend toward minimally invasive surgeries are the major factors that drive the growth of the clot management devices market. However, the high cost associated with these devices and related procedures restrains market growth. Moreover, advancements in technology are expected to offer growth opportunities during the forecast period.
Report coverage & details:
| Report Coverage | Details |
| Forecast Period | 2024–2035 |
| Base Year | 2023 |
| Market Size in 2023 | $2.1 Billion |
| Market Size in 2035 | $4.3 Billion |
| CAGR | 6.2% |
| No. of Pages in Report | 250 |
| Segments covered | Product, End User, and Region |
| Drivers | Rise in prevalence of thromboembolic disorders Surge in trend toward minimally invasive surgeries Developing healthcare infrastructure |
| Opportunity | Technological advancement in the clot management devices |
| Restraint | High cost of clot management devices |
Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/5477
The percutaneous thrombectomy devices segment held the highest market share in 2023.
By product, the percutaneous thrombectomy devices segment held the largest market share in 2023, accounting for two-fifths of the clot management devices market revenue and is estimated to maintain its leadership status throughout the forecast period. This is attributed to the minimally invasive nature of the devices and efficiency in quickly removing clots. Percutaneous thrombectomy devices are designed to physically break down and remove thrombi (blood clots) from blood vessels, offering a less invasive alternative to traditional surgical methods, which can reduce recovery times and lower the risk of complications.
However, the neurovascular embolectomy devices segment is expected to witness the fastest CAGR of 7.0% from 2024 to 2035 owing to increase in prevalence of neurovascular disorders, such as ischemic stroke and cerebral embolism, which require effective and prompt treatment options. Advancements in minimally invasive technologies and rise in awareness among healthcare providers about the benefits of early intervention in stroke management are also contributing factors.
The hospitals segment held the highest market share in 2023.
By end user, the hospitals segment held the largest market share in 2023, accounting for more than two-thirds of the clot management devices market revenue and is estimated to maintain its leadership status throughout the forecast period. This is attributed to the fact that hospitals are primary healthcare facilities that handle many patients with various conditions, including cardiovascular diseases, stroke, and deep vein thrombosis (DVT), which require clot management interventions. Furthermore, hospitals are equipped with the latest medical technology, allowing them to perform complex procedures such as thrombectomies, catheter-directed thrombolysis, and other minimally invasive treatments.
However, the others end user segment is expected to witness the fastest CAGR of 6.6% from 2024 to 2035. This is attributed to the fact that ambulatory surgical centers and specialty clinics often provide more affordable options for patients seeking treatment for clot-related conditions compared to hospitals. This affordability makes them attractive for elective and non-emergency procedures.
North America held the highest market share in 2023.
By region, North America held the largest market share in terms of revenue in 2023, accounting for more than two-fifths of the clot management devices market revenue and is expected to dominate the market during the forecast period. This is attributed to advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and increase in awareness of innovative treatment options. Furthermore, significant investments in medical technology and a robust regulatory framework further support market growth in this region.
However, Asia-Pacific is expected to witness the fastest CAGR of 6.8 % from 2024 to 2035. This is attributed to its rapidly expanding healthcare infrastructure and rise in geriatric population. The government’s investment in healthcare and medical technologies has facilitated the adoption of advanced clot management solutions. In addition, rise in awareness about preventive healthcare and improved access to healthcare facilities further drives the demand for these devices in China.
For Purchase Related Queries/Inquiry – https://www.alliedmarketresearch.com/purchase-enquiry/5477
Leading Market Players: –
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- Koninklijke Philips N.V.
The report provides a detailed analysis of these key players in the Clot management devices market. These players have adopted strategies such as product launch, product approval and agreement to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to highlight the competitive scenario.
Trending Reports in Healthcare Industry:
Global Contraceptives Market Opportunity Analysis and Industry Forecast, 2024-2035
Global Healthcare IT Market Opportunity Analysis and Industry Forecast, 2024-2035
Global Implantable Medical Devices Market Opportunity Analysis and Industry Forecast, 2024-2035
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
